Make us your home page
Instagram

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

FDA studies possible Singulair-suicide tie

WASHINGTON — The Food and Drug Administration said Thursday it is investigating a possible link between Merck's best-selling Singulair and suicide.

The FDA is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.

With sales of $4.3-billion last year, Singulair is used by millions of patients in the United States, according to Merck. First approved in 1998, it's part of a class of asthma and allergy drugs that includes AstraZeneca's Accolate and Critical Therapeutics's Zyflo.

Merck officials stressed that the FDA's inquiry is based on reports, not clinical studies — which are the standard tool for evaluating drug safety. The company said none of the 11,000 patients enrolled in 40 Singulair trials has committed suicide.

"We have no indication that anything about the mechanism of Singulair is consistent with these events," said George Philip, director of research and product development. "But because suicide is a life-threatening event we thought it was important to provide this information in the product label."

Merck recently added reports of suicide to Singulair's label, which already listed suicidal thinking and behavior as reported side effects.

"Patients should not stop taking Singulair before talking to their doctor," the FDA said in its statement, adding that doctors should monitor patients for suicidal behavior and mood changes.

The FDA said it has not established a "causal relationship" between Merck's drug and suicidal behavior. An agency spokeswoman said the review was prompted by three to four suicide reports it received before October.

It could take up to nine months before agency scientists can draw any conclusions, the FDA said in a posting to its Web site.

The agency recently began notifying the public earlier about possible safety issues. The policy change came after the FDA was criticized for acting too slowly on information about the risks of Merck's painkiller Vioxx and GlaxoSmithKline plc's diabetes pill Avandia.

Merck has updated the drug's labeling four times in the past year to include information on a range of reported side effects: tremors, anxiousness, depression and suicidal behavior.

In clinical trials of asthma patients, the most common side effects were headache, flu, abdominal pain and cough.

FDA said it is also reviewing reports of side effects with rival drugs, such as Accolate and Zyflo. Their labeling does not contain language about suicide.

FDA studies possible Singulair-suicide tie 03/27/08 [Last modified: Thursday, March 27, 2008 9:54pm]
Photo reprints | Article reprints

    

Join the discussion: Click to view comments, add yours

Loading...
  1. ICYMI: Florida education news in review, week of July 16, 2017

    Blogs

    Seems like Broward County has started a domino effect. It was the first school board to commit to filing a lawsuit against the state and its controversial education bill, House Bill 7069. Then, the St. Lucie County School Board signed on, too. A running tally of school boards that have reportedly expressed interested in …

    Kali Davis (left), training director for Springboard to Success, helps to coach Justin Black (center), who will be starting his third year of teaching PE at Melrose Elementary, as he works to instruct students in a math lesson during the Spring Board program of Summer Bridge at Woodlawn Elementary School in St. Petersburg.
  2. In advertising, marketing diversity needs a boost in Tampa Bay, nationally

    Business

    TAMPA — Trimeka Benjamin was focused on a career in broadcast journalism when she entered Bethune-Cookman University.

    From left, Swim Digital marketing owner Trimeka Benjamin discusses the broad lack of diversity in advertising and marketing with 22 Squared copywriter Luke Sokolewicz, University of Tampa advertising/PR professor Jennifer Whelihan, Rumbo creative director George Zwierko and Nancy Vaughn of the White Book Agency. The group recently met at The Bunker in Ybor City.
  3. Kushner to testify before two intelligence committees

    Politics

    WASHINGTON— President Donald Trump's senior adviser and son-in-law Jared Kushner is set to make a second appearance on Capitol Hill — he will speak with the House Intelligence Committee on Tuesday, one day after he is scheduled to speak with Senate Intelligence Committee investigators behind closed doors.

    White House senior adviser Jared Kushner is scheduled to testify before the Senate Intelligence Committee and the House Intelligence Committee. [Associated Press]
  4. Rays blow lead in ninth, lose in 10 to Rangers (w/video)

    The Heater

    ST. PETERSBURG — Rays manager Kevin Cash liked the way Alex Cobb was competing Friday night. He liked the way the hard contact made by the Rangers batters went away after the second or third inning. So as the game headed toward the ninth, there was no doubt in Cash's mind that sending Cobb back to the mound was …

    Rays starter Alex Cobb can hardly believe what just happened as he leaves the game in the ninth after allowing a leadoff double then a tying two-run homer to the Rangers’ Shin-Soo Choo.
  5. Exhumation of Dalí's remains finds his mustache still intact

    World

    FIGUERES, Spain — Forensic experts in Spain have removed hair, nails and two long bones from Salvador Dalí's embalmed remains to aid a court-ordered paternity test that may enable a woman who says she is the surrealist artist's daughter to claim part of Dalí's vast estate.

    Salvador Dal? died in 1989 leaving vast estate.